Kymera unveils STAT6 degrader KT-621 (Phase 1 in H2 2024) and TYK2 degrader KT-294 (Phase 1 in H1 2025)

Kymera Therapeutics, Inc.

KT-621 (STAT6 degrader) expected to enter Phase 1 in H2 2024; preclinical data shows superior efficacy to dupilumab.
KT-294 (TYK2 degrader) planned to enter Phase 1 in H1 2025; potential to recapitulate TYK2 loss-of-function biology.
KT-474 (IRAK4 degrader) Phase 2 enrollment in HS and AD expected to complete Q4 2024; topline data H1 2025.
Both KT-621 and KT-294 are wholly-owned, once-daily oral degraders targeting validated autoimmune pathways.
Company holds virtual R&D Day on Jan 4, 2024 to present immunology strategy and new preclinical data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.